Table 2. In vitro contracture test status, 2004–2010 cohort.
| in vitro contracture test | p-value | ||
|---|---|---|---|
| MHN | MHS a | ||
| Number of subjects (%) | 247 (54.4%) | 207 (45.6%) | |
| Demographic data | |||
| Age (mean±sd) | 25.8±5.2 | 25.8±5.4 | 0.96 |
| Sex ratio (M/F) | 225/22 | 199/8 | 0.04 |
| Circumstances | 0.58 | ||
| Cross country | 11 | 13 | |
| Running + jacket | 133 | 111 | |
| Running + load | 53 | 36 | |
| Other | 19 | 19 | |
| Clinical data | |||
| Temperature | 40.1±0.9°C | 40.0±1°C | 0.43 |
| Coma | 130 (53.1%) | 115 (46.9%) | 0.81 |
| Seizures | 11 (64.7%) | 6 (35.3%) | 0.68 |
| Confusion | 111 (53.1%) | 98 (46.9%) | 0.61 |
| Biological data | |||
| Renal failure | 34 (50.7%) | 33 (49.3%) | 0.90 |
| Hepatic failure | 21 (46.7%) | 24 (53.3%) | 0.56 |
Legend: MHN, malignant hyperthermia normal response; MHS, malignant hyperthermia susceptible.
aIncluding MHS for caffeine and MHS for halothane patients.